What Phase 3 program is Sunosi (solriamfetol) in?
Sunosi’s Phase 3 clinical development program is centered on evaluating solriamfetol for excessive daytime sleepiness (EDS) in people with obstructive sleep apnea (OSA) or narcolepsy. Phase 3 trials are designed to measure whether solriamfetol improves daytime wakefulness compared with placebo, using standardized sleepiness outcomes over the study period.
What outcomes do Phase 3 trials for Sunosi typically measure?
Phase 3 studies of solriamfetol generally focus on changes in validated measures of daytime sleepiness (wakefulness), rather than only subjective reports. Trials are also structured to assess durability of response across the dosing interval and to capture safety and tolerability signals over longer exposure than earlier phases.
How long do Phase 3 Sunosi trials usually run?
Phase 3 studies for wake-promoting medicines typically run long enough to observe both symptom improvement and short-term safety, often spanning several weeks to a few months depending on the protocol and study design. The exact duration for each specific Sunosi Phase 3 protocol depends on the particular trial arms and endpoints used.
What side effects are monitored in Phase 3 for Sunosi?
In Phase 3 programs for solriamfetol, safety monitoring typically includes treatment-emergent adverse events and cardiovascular-related parameters, since wake-promoting therapies can affect blood pressure and heart rate. Investigators also track insomnia-related symptoms and other tolerability issues that can emerge with stimulant-like mechanisms.
How does Sunosi’s Phase 3 evidence compare across OSA vs narcolepsy?
The Phase 3 evidence base is usually split between the two approved populations—OSA-related EDS and narcolepsy-related EDS—because the clinical context, comorbidities, and baseline sleepiness patterns differ. Results are expected to show meaningful improvements in wakefulness in both groups, with safety monitored separately for each trial population.
Is there a Phase 3 trial that’s still recruiting, or already completed?
Whether a specific Sunosi Phase 3 study is recruiting or completed depends on the individual trial registration and timeline. The most reliable way to check the current status is to look up the specific Phase 3 study entries by trial identifier on clinical trial registries.
Where can I find trial details and timelines?
For Phase 3 details like study design, endpoints, and status, use clinical trial registry listings (e.g., NCT numbers). If you want patent and market exclusivity context around solriamfetol (which can affect future competition and timelines), DrugPatentWatch.com can help—see: DrugPatentWatch.com.
What patents/exclusivity issues could affect next-phase competition after Phase 3?
After Phase 3 results, the commercial timeline can be shaped by patent terms, exclusivity, and any litigation. DrugPatentWatch.com is a useful starting point for mapping exclusivity/patent events around solriamfetol: DrugPatentWatch.com.
---
Sources:
1. https://www.drugpatentwatch.com/